Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enemas are hypertonic saline osmotic laxatives. They act by drawing water into the colonic lumen, increasing intraluminal pressure and stimulating peristalsis. They typically produce a bowel movement within 2–15 minutes.
## Primary Indications
* Relief of occasional constipation.
* Bowel cleansing prior to rectal examinations or endoscopic procedures.
## Adult Dosing
* **Standard dose:** 1 unit (118 mL delivering 7 g sodium phosphate monobasic and 19 g sodium phosphate dibasic).
* **Frequency:** Maximum 1 dose per 24 hours.
## Pediatric Dosing
* **Children 12 years and older:** Same as adult dose (118 mL).
* **Children 2 to 11 years:** Pediatric size enema (usually 59 mL).
* **Children under 2 years:** Contraindicated.
* *Note: Always verify local institutional nursing protocols, as clinical preference may favor safer alternatives (e.g., glycerin suppositories or saline enemas) in pediatric populations.*
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. High risk of hyperphosphatemia, hypocalcemia, and hypernatremia.
* **Hepatic Impairment:** Use with caution if ascites is present due to potential for fluid/electrolyte shifts.
## Contraindications
* Known hypersensitivity to sodium phosphates.
* Megacolon (congenital or acquired).
* Clinically significant bowel obstruction or perforation.
* Acute surgical abdomen.
* Congestive heart failure or severe, unstable renal disease.
* Children < 2 years of age.
## Adverse Effects
* **Common:** Rectal irritation, burning, or pain.
* **Serious:** Severe electrolyte disturbances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, metabolic acidosis, and acute phosphate nephropathy (calcium phosphate deposition in renal tubules).
## Key Drug Interactions
* **Diuretics (loop/thiazide):** Increases risk of electrolyte imbalance and dehydration.
* **ACE inhibitors/ARBs/NSAIDs:** Concurrent use increases risk of acute kidney injury due to dehydration and potential renal perfusion changes.
* **Calcium channel blockers/Bisphosphonates:** Risk of additive effect on calcium/phosphate levels.
## Monitoring
* **Electrolytes:** Baseline and post-administration serum phosphate, calcium, sodium, and creatinine, particularly in high-risk groups (elderly, renal impairment).
* **Hydration:** Monitor for signs of dehydration (tachycardia, dry mucous membranes, hypotension).
## Clinical Pearls
* **Mechanism:** Works locally in the rectum/sigmoid colon; systemic absorption is minimal in healthy patients but significant in those with inflammatory bowel disease or mucosal damage.
* **Administration:** Lay the patient on the left lateral decubitus position. Lubricate the nozzle and insert gently, aiming toward the umbilicus. Do not force insertion.
* **Safety Warning:** Deaths have been reported due to electrolyte toxicity when used in patients with bowel obstruction or when repeated doses are given in a short timeframe.
* **Transition:** If no bowel movement occurs after one dose, advise the patient to contact a physician; do not administer a second dose.
***
*Disclaimer: This information is for educational purposes only. Clinical guidelines and dosing may vary based on institutional protocols and individual patient factors. Always verify specific drug information, contraindications, and prescribing guidelines with current clinical resources (e.g., Lexicomp, Micromedex) or the manufacturer’s package insert before administering or prescribing.*
